<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715271</url>
  </required_header>
  <id_info>
    <org_study_id>SH-TBL-1</org_study_id>
    <nct_id>NCT02715271</nct_id>
  </id_info>
  <brief_title>Study of TB Lesions Obtained in Therapeutical Surgery</brief_title>
  <acronym>SH-TBL</acronym>
  <official_title>Study of TB Lesions Obtained in Surgery: in Search of Best Biomarkers Correlating With TB Pathology, Clinical Features, MDR Cases and Prognostic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut Germans Trias i Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut Germans Trias i Pujol</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The correlation of the morphologic, microbiological, genetic and histopathological&#xD;
      characteristics of TB lesions obtained in therapeutical surgery with the clinical forms and&#xD;
      features of the patients will provide essential information&#xD;
&#xD;
        1. on the role of the host in the mechanisms associated to the generation and evolution of&#xD;
           active TB and&#xD;
&#xD;
        2. about future diagnostic and/or prognostic biomarkers of TB disease. All this information&#xD;
           could be used for patients stratification and/or to design new therapeutic strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Description of Clinical and Epidemiological Data of the TB patients enrolled</measure>
    <time_frame>at baseline</time_frame>
    <description>for both the Retrospective and Prospective Substudies; descriptive analysis; data recorded in a spreadsheet created ad-hoc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the Histopathological characteristics of the TB lesions of TB patients enrolled</measure>
    <time_frame>at baseline</time_frame>
    <description>for both the Retrospective and Prospective Substudies; descriptive analysis; data recorded in a spreadsheet created ad-hoc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Obtention of a genic-proteomic profile of TB lesions tissues which correlate to the histopathology of the granulomas and/or the clinic-pathological features of TB patients</measure>
    <time_frame>at baseline</time_frame>
    <description>only for Prospective Substudy; descriptive analysis, correlation with histopathological characteristics of TB lesions and with clinical and epidemiological data of TB patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Immunological responses</measure>
    <time_frame>at baseline; and at the moment of discharge, an average of at day 15 post-enrollment</time_frame>
    <description>only for Prospective Substudy. Immunological responses will be measured 2.1.3. Identification of biomarkers in blood at protein level in blood and urine; validation in tissue and blood of genic biomarkers secreted (ELISA, qPCR, immunohistochemistry).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Quality of Life Measurements</measure>
    <time_frame>at baseline (before surgery) and through study completion, an average of 1 year</time_frame>
    <description>measured with Health Quality of Life Questionnaires; only for Prospective Substudy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Thoracic Surgery</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <description>Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>Tuberculosis patients prospectively submitted to therapeutical surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutical surgery for TB</intervention_name>
    <description>Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine</description>
    <arm_group_label>Prospective cohort</arm_group_label>
    <arm_group_label>Retrospective cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For the prospective substudy only:&#xD;
&#xD;
      The following samples will be prospectively collected from patients undergoing therapeutical&#xD;
      surgery:&#xD;
&#xD;
        -  Tissue samples from the TB lesions&#xD;
&#xD;
        -  plasma&#xD;
&#xD;
        -  whole blood for RNA studies&#xD;
&#xD;
        -  urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing therapeutical surgery for their Pulmonary Tuberculosis at NCTLD in&#xD;
        Tbilisi, Georgia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing therapeutical surgery for their Pulmonary Tuberculosis at NCTLD in&#xD;
             Tbilisi, Georgia indicated as per clinical routine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non consenting to donate samples and/or data for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Vilaplana, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut Germans Trias i Pujol (IGTP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <link>
    <url>http://unitatdetuberculosiexperimental.wordpress.com</url>
    <description>website of the Experimental Tuberculosis Unit, Fundacio Institut Germans Trias i Pujol</description>
  </link>
  <results_reference>
    <citation>Vashakidze S, Despuig A, Gogishvili S, Nikolaishvili K, Shubladze N, Avaliani Z, Tukvadze N, Casals M, Caylà JA, Cardona PJ, Vilaplana C. Retrospective study of clinical and lesion characteristics of patients undergoing surgical treatment for Pulmonary Tuberculosis in Georgia. Int J Infect Dis. 2017 Mar;56:200-207. doi: 10.1016/j.ijid.2016.12.009. Epub 2016 Dec 19. Review.</citation>
    <PMID>28007659</PMID>
  </results_reference>
  <results_reference>
    <citation>Benito P, Vashakidze S, Gogishvili S, Nikolaishvili K, Despuig A, Tukvadze N, Shubladze N, Avaliani Z, Vilaplana C. Impact of adjuvant therapeutic surgery on the health-related quality of life of pulmonary tuberculosis patients. ERJ Open Res. 2020 Aug 31;6(3). pii: 00083-2020. doi: 10.1183/23120541.00083-2020. eCollection 2020 Jul.</citation>
    <PMID>32904577</PMID>
  </results_reference>
  <results_reference>
    <citation>Moreira-Teixeira L, Stimpson PJ, Stavropoulos E, Hadebe S, Chakravarty P, Ioannou M, Aramburu IV, Herbert E, Priestnall SL, Suarez-Bonnet A, Sousa J, Fonseca KL, Wang Q, Vashakidze S, Rodríguez-Martínez P, Vilaplana C, Saraiva M, Papayannopoulos V, O'Garra A. Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis. Nat Commun. 2020 Nov 4;11(1):5566. doi: 10.1038/s41467-020-19412-6.</citation>
    <PMID>33149141</PMID>
  </results_reference>
  <results_reference>
    <citation>Fonseca KL, Maceiras AR, Matos R, Simoes-Costa L, Sousa J, Cá B, Barros L, Fernandes AI, Mereiter S, Reis R, Gomes J, Tapia G, Rodríguez-Martínez P, Martín-Céspedes M, Vashakidze S, Gogishvili S, Nikolaishvili K, Appelberg R, Gärtner F, Rodrigues PNS, Vilaplana C, Reis CA, Magalhães A, Saraiva M. Deficiency in the glycosyltransferase Gcnt1 increases susceptibility to tuberculosis through a mechanism involving neutrophils. Mucosal Immunol. 2020 Sep;13(5):836-848. doi: 10.1038/s41385-020-0277-7. Epub 2020 Mar 13.</citation>
    <PMID>32203062</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundació Institut Germans Trias i Pujol</investigator_affiliation>
    <investigator_full_name>Cris Vilaplana</investigator_full_name>
    <investigator_title>Senior Researcher at the Experimental Tuberculosis Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data obtained will be openly available through Mendeley Data, under CC BY 4.0 license.&#xD;
Data set details:&#xD;
Vilaplana, Cristina; Vashakidze, Sergo; Gogishvili, Shota; Nikolaishvili , Keti; Despuig, Albert; Benito, Pau; Avramopoulos, Asimakis; García, Zaira; Téllez, Erica; Sarrias, Maria Rosa (2020), &quot;SH-TBL project dataset&quot;, Mendeley Data, V1, doi: 10.17632/knhvdbjv3r.1</ipd_description>
    <ipd_time_frame>Once the results will be published.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02715271/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

